Novartis launches COPD inhalers in China

Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease.
The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis launches COPD inhalers in China appeared first on MassDevice.

Source: Mass Device - March 22, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Novartis Source Type: news